Evaluation of EPI-X4 as a urinary peptide biomarker for diagnosis and prognosis of late acute GvHD

Bone Marrow Transplant. 2016 Aug;51(8):1137-9. doi: 10.1038/bmt.2016.65. Epub 2016 Apr 4.

Authors

J A Müller¹, O Zirafi¹, N R Roan^{2

3}, S J Lee⁴, J Münch^{1

5}

Affiliations

¹ Institute of Molecular Virology, Ulm University Medical Centre, Ulm, Germany.
² Department of Urology, University of California, San Francisco, CA, USA.
³ Gladstone Institute of Virology and Immunology, The J. David Gladstone Institutes, San Francisco, CA, USA.
⁴ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁵ Ulm Peptide Pharmaceuticals, University of Ulm, Ulm, Germany.

No abstract available

Publication types

Evaluation Study
Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Biomarkers / urine*
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Female
Graft vs Host Disease / diagnosis*
Humans
Male
Middle Aged
Peptide Fragments / urine*
Peptides / urine
Prognosis
Recurrence
Serum Albumin
Time Factors
Young Adult

Substances

Biomarkers
EPI-X4 peptide, human
Peptide Fragments
Peptides
Serum Albumin

Grants and funding

U54 CA163438/CA/NCI NIH HHS/United States